Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First Patient

Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First Patient
A Phase 3 trial evaluating Progenics Pharmaceuticals' new imaging agent to help detect prostate cancer recurrence has begun dosing participants. The agent, called PyL (18F-DCFPyl), is a tracing substance composed of the prostate specific membrane antigen (PSMA)-targeting agent DCFPyL coupled to a radioactive substance called fluorine F 18. PyL is used in positron emission tomography/computed tomography (PET/CT) imaging, a diagnostic tool that uses small amounts of radioactive materials along with a special camera and computer to help evaluate organ and tissue function. After a patient is injected intravenously (into the vein) with the tracing substance, PyL travels through the blood vessels and accumulates at prostate cancer sites, allowing clinicians to determine if the disease has returned or spread to distant organs. “PyL has demonstrated excellent positive and negative predictive values in detecting the presence or absence of prostate cancer. This valuable information has the potential to provide earlier diagnoses, more informed treatment decisions, the ability to monitor responses, and ultimately improve patient outcomes,” Lawrence Saperstein, MD, assistant professor of radiology and biomedical imaging and chief of nuclear medicine at the Yale Smilow Cancer Hospital, and the trial's lead investigator, said in a press release. The open-label CONDOR trial (
Subscribe or to access all post and page content.